Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outc… Read more
Seres Therapeutics Inc (MCRB) - Net Assets
Latest net assets as of September 2025: $43.70 Million USD
Based on the latest financial reports, Seres Therapeutics Inc (MCRB) has net assets worth $43.70 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($143.47 Million) and total liabilities ($99.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $43.70 Million |
| % of Total Assets | 30.46% |
| Annual Growth Rate | 6.66% |
| 5-Year Change | -92.11% |
| 10-Year Change | -93.29% |
| Growth Volatility | 1394.79 |
Seres Therapeutics Inc - Net Assets Trend (2012–2024)
This chart illustrates how Seres Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Seres Therapeutics Inc (2012–2024)
The table below shows the annual net assets of Seres Therapeutics Inc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $13.78 Million | +130.73% |
| 2023-12-31 | $-44.86 Million | -515.99% |
| 2022-12-31 | $10.78 Million | -91.80% |
| 2021-12-31 | $131.51 Million | -24.75% |
| 2020-12-31 | $174.75 Million | +461.62% |
| 2019-12-31 | $-48.32 Million | -0.58% |
| 2018-12-31 | $-48.05 Million | -179.15% |
| 2017-12-31 | $60.70 Million | -54.23% |
| 2016-12-31 | $132.63 Million | -35.43% |
| 2015-12-31 | $205.39 Million | +868.66% |
| 2014-12-31 | $-26.72 Million | -4334.71% |
| 2013-12-31 | $631.00K | -90.08% |
| 2012-12-31 | $6.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Seres Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 97374400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $173.00K | 1.26% |
| Other Components | $991.71 Million | 7194.65% |
| Total Equity | $13.78 Million | 100.00% |
Seres Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Seres Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KAISER REEF LTD.
F:7YR
|
$63.40 Million |
|
Madhya Bharat Agro Products Limited
NSE:MBAPL
|
$63.40 Million |
|
Dundee Corp
PINK:DDEJF
|
$63.40 Million |
|
PUBLIC POLICY HO.COM 144A
F:PD7
|
$63.43 Million |
|
WM Technology Inc
NASDAQ:MAPS
|
$63.37 Million |
|
Manyo Factory Co. Ltd
KQ:439090
|
$63.37 Million |
|
Dyaco International Inc
TW:1598
|
$63.34 Million |
|
Amex Exploration Inc
OTCQX:AMXEF
|
$63.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Seres Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -44,856,000 to 13,784,000, a change of 58,640,000.
- Net income of 136,000 contributed positively to equity growth.
- New share issuances of 23,530,000 increased equity.
- Other factors increased equity by 34,974,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $136.00K | +0.99% |
| Share Issuances | $23.53 Million | +170.71% |
| Other Changes | $34.97 Million | +253.73% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Seres Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.29x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.87x to 5.29x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $3.27 | $9.39 | x |
| 2013-12-31 | $0.32 | $9.39 | x |
| 2014-12-31 | $-13.72 | $9.39 | x |
| 2015-12-31 | $174.56 | $9.39 | x |
| 2016-12-31 | $66.57 | $9.39 | x |
| 2017-12-31 | $30.01 | $9.39 | x |
| 2018-12-31 | $-23.58 | $9.39 | x |
| 2019-12-31 | $-17.06 | $9.39 | x |
| 2020-12-31 | $43.80 | $9.39 | x |
| 2021-12-31 | $28.68 | $9.39 | x |
| 2022-12-31 | $2.00 | $9.39 | x |
| 2023-12-31 | $-7.01 | $9.39 | x |
| 2024-12-31 | $1.77 | $9.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Seres Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 10.14x
- Recent ROE (0.99%) is above the historical average (-283.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -49.15% | 0.00% | 0.00x | 1.03x | $-3.76 Million |
| 2013 | -967.04% | 0.00% | 0.00x | 3.37x | $-6.17 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.04 Million |
| 2015 | -26.67% | 0.00% | 0.00x | 1.06x | $-75.32 Million |
| 2016 | -69.05% | -420.74% | 0.08x | 2.06x | $-104.84 Million |
| 2017 | -147.25% | -278.44% | 0.17x | 3.12x | $-95.45 Million |
| 2018 | 0.00% | -350.03% | 0.23x | 0.00x | $-94.14 Million |
| 2019 | 0.00% | -203.68% | 0.26x | 0.00x | $-65.45 Million |
| 2020 | -51.00% | -268.33% | 0.10x | 1.96x | $-106.60 Million |
| 2021 | -49.87% | -45.25% | 0.41x | 2.70x | $-78.73 Million |
| 2022 | -2319.92% | -3509.50% | 0.02x | 32.35x | $-251.24 Million |
| 2023 | 0.00% | -90.02% | 0.35x | 0.00x | $-109.24 Million |
| 2024 | 0.99% | 0.00% | 0.00x | 10.14x | $-1.24 Million |
Industry Comparison
This section compares Seres Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Seres Therapeutics Inc (MCRB) | $43.70 Million | -49.15% | 2.28x | $63.38 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |